窩客幫-分身行銷廣告平台

Good news!
Glac Biotech’s core strain, Bifidobacterium animalis subsp. lactis CP-9, has officially received GRAS (Generally Recognized as Safe) certification from the U.S. FDA. Following the success of strain MP108, CP-9 marks Glac Biotech’s second strain to earn this prestigious recognition, making the company one of the few in Taiwan to hold multiple GRAS-certified probiotics.

🌍 Why this certification matters
FDA GRAS certification confirms that CP-9 meets the most rigorous international standards of safety and quality, enabling its use across a wide range of food and beverage applications, including:

• Dairy products and plant-based milks

• Sports drinks and juices

• Cereals and nutrition bars

• Infant and toddler foods

This achievement provides Glac’s brand partners with broader, safer ingredient choices — while giving consumers access to more innovative functional food solutions.

🔬 Science-Driven Leadership

• In 2023, Glac Biotech’s MP108 became Asia’s first probiotic strain recognized by the U.S. FDA for use in infant foods (GRN001130).

• CP-9 has been shortlisted for the prestigious NutraIngredients Awards, with scientific studies validating its benefits in gut health and immune modulation.

• With this latest GRAS certification, Glac further strengthens its position as one of Taiwan’s leading probiotic raw material manufacturers trusted worldwide.

🌱 Beyond CP-9: Expanding the Probiotic & Postbiotic Pipeline
Glac Biotech continues to translate scientific data into global health solutions. In addition to CP-9’s GRAS certification, the company is advancing its Totipro® postbiotics across Europe, North America, and Southeast Asia — including regulatory submissions — to meet rising international demand for premium-quality postbiotics.

🚀 Looking Ahead: Science and Partnerships
Since its founding in 2008, Glac Biotech has focused on strain development, patent strategy, clinical validation, and international certifications. The GRAS recognition for CP-9 not only represents years of investment, but also opens new doors for collaboration with leading global brands.

In the years ahead, Glac Biotech will continue to:

• Validate and expand the applications of its probiotic and postbiotic portfolio

• Broaden its range of GRAS-certified strains and postbiotic solutions

• Deepen partnerships with global brands and OEM clients to co-high-quality products that meet international standards for safety and efficacy

Media Coverage

Glac Biotech Secures U.S. Food and Drug Administration GRAS Approval for Probiotic Strain CP-9 | AP News